Table 2.

Characteristics of the Matched-pair Groups

Characteristic	TBF (n = 142)	Treo (n = 142)	P-value
Median age at transplant, y (range)	58 (21–72)	58 (18–76)	0.47
Patient gender
Male	81 (57)	83 (59)	0.81
Female	61 (43)	59 (41)
Secondary AML	13 (9)	22 (16)	0.1
Cytogenetic risk (MRC)			0.52
Good	7 (5)	9 (6)
Intermediate	84 (59)	91 (64)
Adverse	23 (17)	23 (17)
Missing	28 (19)	19 (13)
FLT3-ITD mutation			0.79
FLT3-ITD	28 (34)	30 (36)
FLT3 wt	54 (66)	53 (64)
Missing	60	59
NPM1 mutation			0.65
NPM1 mutated	33 (42)	29 (39)
NPM1 wt	45 (58)	46 (61)
Missing	64	67
Disease status at HSCT			1
CR1	116 (82)	116 (82)
CR2	26 (18)	26 (18)
Karnofsky performance score			0.38
≥90	116 (82)	119 (84)
<90	26 (18)	23 (16)
Median year of HSCT (range)	2019 (2014–2020)	2019 (2012–2020)	0.39
Conditioning intensity			1
MAC	75 (53)	75 (53)
RIC	67 (47)	67 (47)
GVHD prophylaxis (other than PTCy)
MMF + ciclosporine	95 (67)	25 (18)
MMF + tacrolimus	27 (19)	50 (35)
MMF + sirolimus	4 (3)	60 (42)
Other	16 (11)	7 (5)
ATG			0.59
Yes	19 (13)	16 (11)
No	123 (87)	126 (89)
Stem cell source			1
PBSC	124 (87)	124 (87)
BM	18 (13)	18 (13)
Female donor/male recipient	31 (22)	31 (22)	1
Median follow-up, mo (95% CI)	15 (12-24)	18 (14-22)	0.5

AML = acute myeloid leukemia; ATG = antithymocyte globulin; BM = bone marrow; CI = confidence interval; CR = complete remission; HSCT = hematopoietic stem cell transplant; MAC = myeloablative conditioning; MMF = mycophenolate mofetil; MRC = Medical Research Council Cytogenetic Classification; PBSC = peripheral blood stem cells; RIC = reduced intensity conditioning; TBF = thiotepa, busulfan, fludarabine; Treo = treosulfan-based regimen; wt = wild type.

Unless otherwise noted, data are expressed as n (%).